RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems.The “off-the-shelf” cell banks and bioprocess media products that RoosterBio has commercialized are designed to remove years of time, and millions of dollars, from traditional mesenchymal cell therapeutic product development efforts. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development. RoosterBio’s diverse team of technology disrupters and thought leaders are ushering in a new era of productivity and standardization into the field with innovative products, accelerating the road to discovery in regenerative medicine.
RoosterBio launched its first line of cGMP-grade hMSC products in 2018 that are capable of being directly used as starting materials within clinical manufacturing processes, enabling their customers to reach the clinic with their regenerative medicine innovations more rapidly than ever before. Now with over 50 products available, RoosterBio serves more than 200 customers in 18 countries with a corporate focus to expand even further into the global market.
For more information on RoosterBio, please visit http://www.roosterbio.com